147 related articles for article (PubMed ID: 27917084)
1. Sofosbuvir and Simeprevir Combination Therapy for HCV Genotype 1 Infection: Results of a Single-Center VA Experience.
Sclair SN; Hernandez MD; Vance E; Gilinski D; Youtseff H; Toro M; Antoine M; Jeffers LJ; Peyton A
Gastroenterol Hepatol (N Y); 2016 Aug; 12(8):490-497. PubMed ID: 27917084
[TBL] [Abstract][Full Text] [Related]
2. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
[TBL] [Abstract][Full Text] [Related]
3. Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES.
Butt AA; Yan P; Marks K; Shaikh OS; Sherman KE;
Aliment Pharmacol Ther; 2016 Oct; 44(7):728-37. PubMed ID: 27459341
[TBL] [Abstract][Full Text] [Related]
4. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Pearlman BL; Ehleben C; Perrys M
Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
[TBL] [Abstract][Full Text] [Related]
5. Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4.
Ahmed S; Hassan E; Gomaa A; Esamat G; Ramadan A; Ahmed M; Elsayed A; A Wahsh E
Curr Drug Saf; 2023; 18(2):207-213. PubMed ID: 35538812
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
7. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
Pillai AA; Wedd J; Norvell JP; Parekh S; Cheng N; Young N; Spivey JR; Ford R
Am J Gastroenterol; 2016 Feb; 111(2):250-60. PubMed ID: 26832650
[TBL] [Abstract][Full Text] [Related]
8. Simeprevir and sofosbuvir for treatment of hepatitis C infection.
Chopp S; Vanderwall R; Hult A; Klepser M
Am J Health Syst Pharm; 2015 Sep; 72(17):1445-55. PubMed ID: 26294237
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Ioannou GN; Beste LA; Chang MF; Green PK; Lowy E; Tsui JI; Su F; Berry K
Gastroenterology; 2016 Sep; 151(3):457-471.e5. PubMed ID: 27267053
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
Degré D; Sersté T; Lasser L; Delwaide J; Starkel P; Laleman W; Langlet P; Reynaert H; Bourgeois S; Vanwolleghem T; Negrin Dastis S; Gustot T; Geerts A; Van Steenkiste C; de Galocsy C; Lepida A; Orlent H; Moreno C
PLoS One; 2017; 12(1):e0170933. PubMed ID: 28125694
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
Beck KR; Kim N; Khalili M
Dig Dis Sci; 2016 Dec; 61(12):3602-3608. PubMed ID: 27743164
[TBL] [Abstract][Full Text] [Related]
12. Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).
Buti M; Calleja JL; Lens S; Diago M; Ortega E; Crespo J; Planas R; Romero-Gómez M; Rodríguez FG; Pascasio JM; Fevery B; Kurland D; Corbett C; Kalmeijer R; Jessner W
Aliment Pharmacol Ther; 2017 Feb; 45(3):468-475. PubMed ID: 27896822
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.
Gutierrez JA; Carrion AF; Avalos D; O'Brien C; Martin P; Bhamidimarri KR; Peyton A
Liver Transpl; 2015 Jun; 21(6):823-30. PubMed ID: 25825070
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
Gayam V; Tiongson B; Khalid M; Mandal AK; Mukhtar O; Gill A; Garlapati P; Shrestha B; Khalid M; Chakraborty S; Guss D; Sherigar J; Mansour M; Mohanty S
Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1200-1207. PubMed ID: 30096090
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S
Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562
[TBL] [Abstract][Full Text] [Related]
16. A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013: The 64th Annual Meeting of the American Association for the Study of Liver DiseasesNovember 1-5, 2013 • Washington DCSpecial Reporting on:• Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Genotype 1 HCV Infection• Novel Interferon- and Ribavirin-Free Regimen Results in SVR12 Rates of Over 90% in HCV Genotype 1b Infection• Studies Confirm Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Genotype 1 Subpopulations• All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV• Faldaprevir Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in DifficuIt-to-Treat HCV Infection• Once Daily Sofosbuvir/Ledipasvir Combination Elicits Rapid Decline in HCV RNAPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDWeill Cornell Medical CollegeNew York, New York.
Gastroenterol Hepatol (N Y); 2014 Jan; 10(1 Suppl 1):1-19. PubMed ID: 25337060
[No Abstract] [Full Text] [Related]
17. Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.
Langness JA; Tabano D; Wieland A; Tise S; Pratt L; Harrington LA; Lin S; Ghuschcyan V; Nair KV; Everson GT
Ann Hepatol; 2017; 16(3):366-374. PubMed ID: 28425406
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
[TBL] [Abstract][Full Text] [Related]
19. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Lawitz E; Sulkowski MS; Ghalib R; Rodriguez-Torres M; Younossi ZM; Corregidor A; DeJesus E; Pearlman B; Rabinovitz M; Gitlin N; Lim JK; Pockros PJ; Scott JD; Fevery B; Lambrecht T; Ouwerkerk-Mahadevan S; Callewaert K; Symonds WT; Picchio G; Lindsay KL; Beumont M; Jacobson IM
Lancet; 2014 Nov; 384(9956):1756-65. PubMed ID: 25078309
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.
Maasoumy B; Vermehren J; Welker MW; Bremer B; Perner D; Höner Zu Siederdissen C; Deterding K; Lehmann P; Cloherty G; Reinhardt B; Pawlotsky JM; Manns MP; Zeuzem S; Cornberg M; Wedemeyer H; Sarrazin C
J Hepatol; 2016 Sep; 65(3):473-82. PubMed ID: 27085252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
